Protection against tuberculosis: cytokines, T cells, and macrophages
Open Access
- 1 November 2002
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 61 (Supplement), 54ii-58
- https://doi.org/10.1136/ard.61.suppl_2.ii54
Abstract
Tuberculosis remains a major health problem, with two million deaths and eight million new cases annually. At the same time, two billion people (one third of the total world population) are infected with the aetiological agent, Mycobacterium tuberculosis. Of these, fewer than 10% ever develop disease, although the pathogen is not eradicated but rather contained in discrete lesions. Hence, the immune system is highly effective in containing the pathogen, but fails to eradicate it. Disease typically develops through reactivation once the immune system is weakened. The immune response to M tuberculosis is T cell dependent. It comprises not only the conventional CD4 and CD8 T cells, but also γδ T cells and CD1 restricted T cells. γδ T cells recognise phospholigands and no presentation molecules are known thus far. CD1 restricted T cells recognise glycolipids, which are highly abundant components of the mycobacterial cell wall. Although different T cells are required for optimum protection, the immune mechanisms known to have a role in acquired resistance can be associated with two major mechanisms: (a) activation of macrophages by cytokines; (b) direct cytolytic activity. In vivo granuloma formation, which is central to protection, is induced and sustained by cytokines. Mycobacteria are contained within granulomas and in this way are prevented from spreading all over the body.This publication has 7 references indexed in Scilit:
- How can immunology contribute to the control of tuberculosis?Nature Reviews Immunology, 2001
- Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting PathologyInfection and Immunity, 2001
- Secreted Lymphotoxin-α Is Essential for the Control of an Intracellular Bacterial InfectionThe Journal of Experimental Medicine, 2001
- Is the development of a new tuberculosis vaccine possible?Nature Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Role of Cytokines in TuberculosisImmunobiology, 1993